European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

Description du projet

L’horloge circadienne tourne pour la maladie d’Alzheimer

De nombreux processus biologiques, y compris le sommeil, la libération d’hormones et les habitudes alimentaires, suivent un rythme circadien, un cycle de 24 heures qui fait partie de notre horloge interne. La perturbation des rythmes circadiens est liée à des maladies comme la maladie d’Alzheimer (MA). De nombreux gènes responsables de l’horloge circadienne sont anormalement exprimés dans la MA, la transformant en une cible médicamenteuse putative. Financé par le programme Actions Marie Skłodowska-Curie, le projet TClock4AD vise à développer de nouveaux médicaments qui ciblent l’horloge circadienne. Les chercheurs examineront les mécanismes moléculaires qui régissent les rythmes circadiens dans la MA, identifieront les cibles thérapeutiques et développeront des composés conçus de manière rationnelle, dont l’efficacité sera testée dans des modèles de criblage innovants.

Objectif

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes regulating memory, sleep, and neurodegeneration have altered expression profiles in AD, CC has recently emerged as a viable therapeutic target for new effective drugs. However, how to develop them remains a fundamental challenge. The “Targeting Circadian Clock Dysfunction in Alzheimer’s Disease” Doctoral Network (TClock4AD) is proposed to create a new generation of researchers able to face such challenge by harnessing neurobiology, medicinal chemistry, pharmaceutical nanotechnology, neuroimmunology, big data, bioinformatics, and entrepreneurship. TClock4AD will exploit unique expertise and advanced technologies at 10 leading universities, 3 research centers, a hospital, 10 non-academic institutions including SMEs, a large pharma company, a Health industry association, and a patient organization across EU, UK, Israel, USA and China. TClock4AD will deliver double degrees to 15 doctoral candidates, with triple-i knowledge/skills, broad vision and a business-oriented mindset. Their research activities will be structured around 5 scientific themes to: (1) develop novel artificial intelligence-, proteolysis targeting chimeras- and multitarget-based strategies for new CC drug candidates (2) develop novel drug delivery nanotechnologies, which take into consideration CC (3) investigate innovative in vitro (stem-cells, 3D cultures) & in vivo (Drosophila), as well as organ-on-chip techniques, for preclinical validation of CC drugs (4) get insight into the molecular mechanisms underlying CC in AD and associated drug response in mice and C. elegans models (5) develop innovative biotech business model and exploitation strategies.

Coordinateur

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Contribution nette de l'UE
€ 778 312,80
Adresse
VIA ZAMBONI 33
40126 Bologna
Italie

Voir sur la carte

Région
Nord-Est Emilia-Romagna Bologna
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Participants (12)

Partenaires (14)